

Life-threatening bleeding under vitamin K antagonists in spite of an INR in the therapeutic range

Mathilde Gavillet · Claire Abbal · Sabine Schmidt ·
Jasmine Nötzli · Jean-François Lambert ·
Anne Angelillo-Scherrer

Published online: 18 March 2011
© Springer Science+Business Media, LLC 2011

Keywords Oral anticoagulation · Factor IX · Propeptide mutation · Vitamin K antagonists · Prosthetic heart valve

The major risk associated with the use of vitamin K antagonists (VKA) is haemorrhage, which might be severe or even life-threatening. In clinical studies where anticoagulation intensity was carefully monitored, treatment with VKA increases the risk of major bleeding by 0.3–0.5% per year when compared to controls [1]. In randomized trials including patients with mechanical heart valves, VKA treatment was associated with a risk of major bleeding ranging between 1 and 8.3% [1]. However, in clinical practice, the rates are less consistent [1]. The major determinants of VKA-induced bleeding are the intensity of the anticoagulant effect, the patient characteristics, the concomitant use of drugs that interfere with hemostasis, and the length of therapy [1].

Here, we report a case of a rare hypersensitivity to VKA due to a mutation of factor IX (FIX) propeptide in the context of a prosthetic mechanical heart valve.

In November, 2008, a 62-year-old man presented with an obstructive laryngeal hematoma (Fig. 1a, b) after tongue biting requiring intratracheal intubation. His medical history

revealed prosthetic mechanical aortic valve replacement in July 2008 (Bentall procedure, Cardiomedic prosthesis). Oral anticoagulation with VKA (acenocoumarol) was initiated post-operatively. When the laryngeal hematoma appeared, the patient's International Normalized Ratio (INR) was 3.5. In December, 2008, the patient was admitted to the intensive care unit with a massive hemothorax (Fig. 1c) occurring 10 days after a reintervention to cure a paraprosthetic leak, and requiring surgical drainage. INR was 1.3. The patient's and his relatives reported no history of bleeding. Aspirin, the only patient's medication favoring bleeding, had been stopped 4 days before the first bleeding episode. Before the introduction of acenocoumarol, blood count, prothrombin time (PT) and activated partial thromboplastin time (APTT) were within the normal range.

Coagulation tests are listed in Fig. 1d. Both major bleeding episodes were accompanied by INR values within or even below the therapeutic range (therapeutic range for a mechanical valve carrier: 2.5–3.5) [2]. However, APTT was abnormally prolonged because FIX was exaggeratedly lower than the other vitamin K dependant factors (II, VII, X). Factor V, VIII, XI and XII were within the normal range during both bleeding episodes. APTT and FIX both normalized after vitamin K supplementation and bleeding did not recur.

Genomic DNA was purified from the patient whole blood, and FIX exon 2 was amplified using the forward primer 5'-catgccctaaagagaattggct-3' and the reverse primer 5'-tgcactgaagggtattatgtgg-3'. The thermocycling conditions of the PCR were 30 s 94°C, 1 min 53°C, and 1 min 72°C, for 40 cycles. Direct sequencing of the PCR product showed a single guanosine-to-adenosine transition at nucleotide 109 (numbered from genBank accession gi180552) causing the substitution of alanine at locus-10 (Ala-10) by threonine in the FIX propeptide (Fig. 2a).

M. Gavillet · C. Abbal · J. Nötzli · J.-F. Lambert ·
A. Angelillo-Scherrer (✉)
Service and Central Laboratory of Hematology, Centre
Hospitalier Universitaire Vaudois and University of Lausanne,
rue du Bugnon 46, CH-1011 Lausanne, Switzerland
e-mail: Anne.Angelillo-Scherrer@chuv.ch

S. Schmidt
Department of Radiology, Centre Hospitalier Universitaire
Vaudois and University of Lausanne, rue du Bugnon 46,
CH-1011 Lausanne, Switzerland




Fig. 1 a (axial) and b (sagittal) CT of the neck, showing an obstructive laryngeal hematoma (arrow heads). c CT of the chest showing a right hemothorax (arrow heads). d Table including coagulation tests

Fig. 2 a Schematic representations of, upper line, FIX gene (accession number M11309), and, lower line, FIX propeptide. The mutation is indicated by an arrow line [6]. Exons are numbered. G guanosine, A adenosine, GLA Vitamin K-dependent carboxylation/gamma-carboxyglutamic domain, EGF Epidermal growth factor-like domain, B family pedigree. Affected males in black, female carriers in stripes, wild type phenotype in white, unknown phenotype in grey, deduced phenotypes circled with grey. Arrow head indicates the index patient




Table 1 Summary of all similar cases published

#	Reference	Date	Origin	Age at Dn	Anticoagulation indication	Bleeding sites	Basal FIX level (%)	FIX Level under anticoagulation (%)	Other coagulation tests under anticoagulation	Mutation type	Alternative therapy proposed/used
1	3	1996	USA	49	Mechanical prosthetic aortic valve replacement	Hemorrhax, hematuria, and ecchymoses over the arms, legs, and trunk	120–148	<1	PT 23.7%, APTT > 150 s, FVII 42%, FVIII > 200%	Ala-10 → Thr	Low dose warfarin, with target: no PT prolongation (FIX 16%, FVII 80%, FX 43%). C: free of thrombotic and hemorrhagic complications. Long term heparin.
2	4, 13	1997	Germany	66	Mechanical prosthetic aortic valve replacement	Severe muscle bleeding	55	<1	PT 45%, APTT 70.9 s, FII 50%, FVII 31%, FX 22%	Ala-10 → Val	Long term heparin.
3	4	1997	Germany	38	Mechanical prosthetic aortic valve replacement	Bleeding in scrotum and muscle	55	<1	PT 50%, APTT 59.1 s, FII 66%, FVII 44%, FX 46%	Ala-10 → Thr	Long term heparin.
4	4, 13	1997	Germany	30	Deep vein thrombosis	Severe muscle bleeding	125	1	PT 29%, APTT 106 s, FII 35%, FVII 19%, FX 13%	Ala-10 → Val	Long term heparin.
5	14, 13	1997	Germany	66	Mechanic prosthetic aortic valve replacement	Major epistaxis, severe muscle bleeding	80	3	INR 1.6, APTT 70.9 s, FV 92%, FVII 31%, FVIII 260%, FX 22%, FXI 79%, FXII 122%	n.a.	Long term heparin.
6	14, 13	1997	Germany	38	Mechanic prosthetic aortic valve replacement	Muscle and scrotal bleeding	48	2	INR 1.4, APTT 59.1 s, FV 69%, FVII 44%, FVIII 112%, FX 46%, FXI 75%, FXII 66%	n.a.	Long term heparin. C: no complication.
7	8	1995	Germany	29	Deep vein thrombosis, as part of an antiphospholipid-antibody syndrome	Severe muscle bleeding	120	1	PT 29%, APTT 106 s, FV 94%, FVII 19%, FVIII 69%, FX 13%, FXI 138%, FXII 87%	Ala-10 → Val	Aspirin 100 mg/d plus low molecular weight heparin 5000 IU/d.
8	7, 13	2000	UK	56	Deep vein thrombosis secondary to carcinoma of the stomach	Severe muscle bleeding	65	<1	INR 2.2, APTT 104–170 s, FVII 20%	Ala-10 → Thr	Low molecular weight heparin.
9	12	2001	Germany	66	Mechanical prosthetic aortic valve replacement	Severe muscle bleeding	88	2	APTT > 140 s, other vitamin K dependant factors 20–50%	Ala-10 → Val	Replacement of the prosthetic mechanical valve with a biological device.
10	13	2001	Germany	45	Pulmonary embolism	Epistaxis, hematuria, muscle bleeding and atraumatic haemarthrosis	Normal	<5	APTT > 150 s, FII 18%, FVII 11%, FX 6%	Ala-10 → Val	Alternative anticoagulation therapy.

Table 1 continued

#	Reference	Date	Origin	Age at Dn	Anticoagulation indication	Bleeding sites	Basal FIX level (%)	FIX level under anticoagulation (%)	Other coagulation tests under anticoagulation	Mutation type	Alternative therapy proposed/used
11	13	2001	Germany	66	Mechanical prosthetic aortic valve replacement	Muscle and soft tissue bleeding	Normal	<1	APTT>120sec, FII 34%, FVII 64%	Ala-10 → Val	Alternative anticoagulation therapy.
12	13	2001	Switzerland	77	Mechanical prosthetic aortic valve replacement	Muscle and retroperitoneal bleeding	Normal	3	INR 1.9, APTT 80 s	Ala-10 → Thr	Alternative anticoagulation therapy.
13	13	2001	USA	13	Mechanical prosthetic aortic valve replacement	n.a.	Normal	6	“disproportional” APTT	Ala-10 → Thr	Alternative anticoagulation therapy.
14	10	2002	Denmark	62	Mechanical prosthetic aortic valve replacement	Severe muscle bleeding	n.a.	4	INR 1.9, APTT 128 s	Ala-10 → Thr	(1) Aspirin 100 mg/d. C: myocardial infarction, cerebral thrombosis, acute and a transient ischemic attack. (2) Aspirin 100 mg/2d + low dose warfarin with FIX monitoring (target 10–20%) C: 4 episodes of gastrointestinal bleedings. (3) Low dose warfarin with FIX monitoring (target 8–16%). C: neither bleedings nor thromboses.
15	6, 11, 13	2001	Switzerland	58	Mechanical prosthetic aortic valve replacement	Muscle bleeding, hemarthrosis, intestinal wall bleeding, laryngeal hematoma	95	3	INR 1.5, APTT 77.3 s, FII 56%, FV 90%, FVII 78%, FVIII 187%, FX 27%, FXI 102%	Ala-10 → Val	(1) Full dose low molecular weight heparin. C: thrombus on the artificial heart valve with recurrent cerebral ischemia episodes. (2) Aspirin 100 mg/d added. C: idem. (3) Aortic valve replacement with biological prosthesis. C: no further complication.
16	6, 13	2001	Switzerland	63	Thrombosis prophylaxis after hip replacement surgery (severe heparin allergy)	Major subcutaneous hematoma	n.a.	2	INR 2.8, APTT 164 s, FVIII 270%	Ala-10 → Thr	Stop anticoagulation (prophylaxis). C: no further bleeding complication.

Table 1 continued

#	Reference	Date	Origin	Age at Dn	Anticoagulation at indication	Bleeding sites	Basal FIX level (%)	FIX Level under anticoagulation (%)	Other coagulation tests under anticoagulation	Mutation type	Alternative therapy proposed/used
17	15	2008	Switzerland	70	Biological prosthetic aortic valve replacement	Soft tissue, muscle and joint bleeding	n.a.	2	INR 2.1, APTT 78 s, FII 46%, FVII 29%	Ala-10 → Thr	Stop anticoagulation.
18	9	2010	Switzerland	53	Mechanical prosthetic mitral valve replacement	Subcutaneous bleeding, hemarthrosis and haematoma of the epiglottis	n.a.	<1	INR 2.9, APTT 76 s, FII 30%, FV 112%, FVII 16%, FVIII 263%, FX 8%, FXI 135%	Ala-10 → Thr	Low dose phenprocoumon with monitoring of FIX level (target 5–15%).
19	Present case	2011	Switzerland	62	Mechanical prosthetic aortic valve replacement	Laryngeal hematoma and postoperative hemothorax	80	1	INR 3.5, APTT 142 s, FII 20%, FV 145%, FVII 11%, FX 11%, FVIII 185%, FXI 110%, FXII 110%	Ala-10 → Thr	Full dose low molecular weight heparin.

When publication mentions a whole family, only the index case is listed. *Dn* diagnosis, *C* comment on the outcome, *INR* international normalized ratio, *PT* prothrombin time, *APTT* activated partial thromboplastin time, *FII* factor II, *FVII* factor VII, *FVIII* factor VIII, *FIX* factor IX, *FX* factor X, *FXI* factor XI, *FXII* factor XII. Ala-10 → Val alanine residue at position-10 to threonine substitution. Ala-10 → Val alanine residue at position-10 to valine substitution. *n.a.* Information not available

Screening of patient's relatives allowed to identify seven further asymptomatic carriers (two males, five females) (Fig. 2b).

Because of the severe bleeding complications presented by our patient, the oral anticoagulation was replaced by low molecular weight heparin at therapeutic dose monitored by anti-Xa activity in order to be sure that anti-Xa activity levels were maintained within the therapeutic range. 15 months later no recurrence of bleeding nor thrombotic complication were observed.

In the literature, two point mutations causing Ala-10 substitution by either a valine (Ala-10Val) or a threonine (Ala-10Thr) have been described [3, 4]. Ala-10 is located at the essential recognition site for the γ -carboxylase [5] and is highly conserved in all vitamin K-dependent coagulation factors [6]. Ala-10Val and Ala-10Thr FIX variants display a more than 30-fold lower affinity for the γ -carboxylase than the wild type propeptide [3]. The affinity of the mutated enzymatic peptide complex for reduced vitamin K is decreased when compared to the enzymatic complex comprising the wild type peptide [3]. Consistently, the γ -carboxylation of these FIX variants is less efficient and becomes dramatically impaired in patients with VKA medication [3].

Male patients have a normal or slightly lowered basal FIX level. However, under VKA therapy, they display a dramatic decrease of FIX activity that is out of proportion with the other vitamin K dependant coagulation factors (II, VII, X). APTT is thus abnormally prolonged, while PT and INR remain within, or even below, the therapeutic range; and patients exhibit severe and sometimes life-threatening soft tissue and muscle bleeding [3, 4, 7–16]. From time to time misdiagnosed for mild hemophilia B, patients carrying a FIX propeptide mutation can be distinguished by an absence of self or family bleeding history as well as normalization of APTT and FIX level after vitamin K administration. Because FIX gene is located on chromosome X, males are more affected than females. One female patient carrier of the Ala-10Val mutation was treated by VKA [17]. When INR was 2.3, FIX level was 16%. This patient did not develop bleeding complications [17].

So far 18 similar cases have been reported in the literature worldwide [3, 4, 7–16] (Table 1). Systematic screening in 4039 individuals yielded no further case [4, 18–20]. Therefore, prevalence of Ala-10Thr or Ala-10Val variants in the population is estimated to range from 1/1,000 to 1/10,000 and systematic screening prior to initiating oral anticoagulation is not indicated. However it is worth noticing that about one-third of these patients (6/19) originate from Switzerland including our current reported case. Although selection bias is possible, one study using haplotype analysis revealed a founder effect in the five German

and Swiss patients carrying a FIX variant (1 Ala-10Val and 4 Ala-10Thr) derived from a common founder [14]. We postulate that the prevalence of this genetic variant may be higher in the Swiss population. APTT screening is certainly of interest in any bleeding patient with INR values within the therapeutic range, especially in male patients. If abnormally prolonged, quantitative determination of FIX level can lead to the diagnosis. Further use of VKA is not recommended. For the present being, low molecular weight heparins represent an inconvenient but safe alternative. An alternative could be to monitor FIX activity targeting a level of 5–15%, as previously described [3, 10, 11]. We did not choose this therapeutic option for our patient as he presented a severe bleeding episode with a FIX level at 10% (Fig. 1d). The replacement of the prosthetic mechanical valve by a biological graft in order to avoid anticoagulation was discussed but the risk of morbidity and mortality associated with cardiac surgery was considered to be too high. In the future, patients with FIX propeptide mutation may benefit from the novel oral anti-thrombin and anti-Xa inhibitors, yet further validation studies are needed.

Acknowledgments We thank Drs. M. Wicki, B. Portmann and Zimerli for participating in the screening part of the study.

References

- Schulman S, Beyth RJ, Kearon C, Levine MN (2008) Hemorrhagic complications of anticoagulant and thrombolytic treatment: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). *Chest* 133(6 Suppl): 257S–298S. doi:10.1378/chest.08-0674
- Salem DN, O’Gara PT, Madias C, Pauker SG (2008) Valvular and structural heart disease: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). *Chest* 133(6 Suppl):593S–629S. doi:10.1378/chest.08-0724
- Chu K, Wu SM, Stanley T, Stafford DW, High KA (1996) A mutation in the propeptide of factor IX leads to warfarin sensitivity by a novel mechanism. *J Clin Invest* 98(7):1619–1625. doi:10.1172/JCI118956
- Oldenburg J, Quenzel EM, Harbrecht U, Fregin A, Kress W, Muller CR, Hertfelder HJ, Schwaab R, Brackmann HH, Hanfland P (1997) Missense mutations at ALA-10 in the factor IX propeptide: an insignificant variant in normal life but a decisive cause of bleeding during oral anticoagulant therapy. *Br J Haematol* 98(1):240–244
- Jorgensen MJ, Cantor AB, Furie BC, Brown CL, Shoemaker CB, Furie B (1987) Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. *Cell* 48(2):185–191. doi:0092-8674(87)90422-3[pii]
- Furie B, Furie BC (1988) The molecular basis of blood coagulation. *Cell* 53(4):505–518
- Aegerter C, Fontana S, Fux C, Demarmels Biasiutti F (2003) Life threatening bleeding under adequate oral anticoagulation. Cases 4a, b. *Hamostaseologie* 23(3):113–116. doi:10.1267/Hamo03030113
- Baker P, Clarke K, Giangrande P, Keeling D (2000) Ala-10 mutations in the factor IX propeptide and haemorrhage in a patient treated with warfarin. *Br J Haematol* 108(3):663
- Harbrecht U, Oldenburg J, Klein P, Weber D, Rockstroh J, Hanfland P (1998) Increased sensitivity of factor IX to phenprocoumon as a cause of bleeding in a patient with antiphospholipid antibody associated thrombosis. *J Intern Med* 243(1):73–77
- Holbro A, Marbet GA, Tran TH, Oldenburg J, Friesewinkel O, Tsakiris DA (2010) Prosthetic heart valves and rare hypersensitivity to vitamin K antagonists resulting from factor IX mutation: how to manage anticoagulation? *Haemophilia* 16(1):187–189. doi:10.1111/j.1365-2516.2009.02115.x
- Kristensen SR (2002) Warfarin treatment of a patient with coagulation factor IX propeptide mutation causing warfarin hypersensitivity. *Blood* 100(7):2676–2677
- Lammle B (2003) Clinical problems with oral anticoagulation—3 case reports. *Ther Umsch* 60(1):63–66
- Neuhaus T, Hertfelder HJ, Hess L, Oldenburg J, Walger P, Vetter H (2001) An uncommon cause of severe soft tissue bleeding during phenprocoumon treatment. *Dtsch Med Wochenschr* 126(25–26):754–756. doi:10.1055/s-2001-15099
- Oldenburg J, Kriz K, Wuillemin WA, Maly FE, von Felten A, Siegemund A, Keeling DM, Baker P, Chu K, Konkle BA, Lammle B, Albert T (2001) Genetic predisposition to bleeding during oral anticoagulant therapy: evidence for common founder mutations (FIXVal-10 and FIXThr-10) and an independent CpG hotspot mutation (FIXThr-10). *Thromb Haemost* 85(3):454–457
- Quenzel EM, Hertfelder HJ, Oldenburg J (1997) Severe bleeding in two patients due to increased sensitivity of factor IX activity to phenprocoumon therapy. *Ann Hematol* 74(6):265–268
- Ulrich S, Brand B, Speich R, Oldenburg J, Asmis L (2008) Congenital hypersensitivity to vitamin K antagonists due to FIX propeptide mutation at locus -10: a (not so) rare cause of bleeding under oral anticoagulant therapy in Switzerland. *Swiss Med Wkly* 138(7–8):100–107
- Bestmann L, Zuger M, Oldenburg J, Buhler D, Maly FE (2001) Coagulation factor IX propeptide mutations causing coumarin hypersensitivity: identification of female alanine-10 valine heterozygotes. *Thromb Haemost* 85(3):567–568
- Peters J, Luddington R, Brown K, Baglin C, Baglin T (1997) Should patients starting anticoagulant therapy be screened for missense mutations at Ala-10 in the factor IX propeptide? *Br J Haematol* 99(2):467–468
- Tassies D, Monteagudo J, Maragall S, Ordinas A, Reverter JC (2005) No impact of factor IX Ala-10 mutations in acenocoumarol-treated southern Europeans. *Blood Coagul Fibrinolysis* 16(8):563–566
- van der Meer FJ, Vos HL, Rosendaal FR (1999) No indication for APTT screening in patients on oral anticoagulant therapy. *Thromb Haemost* 81(3):364–366